Blog
71 Articles
Cracking the KRAS Code
Dr. Despina Siolas is focusing her research on new treatments for pancreatic cancer, particularly ones that go after KRAS mutations.
Final Results of the Daraxonrasib Trial Are Unprecedented
When Dr. Brian Wolpin read the final results from the phase III daraxonrasib trial, everyone was on their feet at the 2026 ASCO meeting.
Accessing Daraxonrasib: A Quick Primer
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you.
2026 AACR Annual Meeting Gives Hope for the Future
Research highlights from the 2026 AACR Meeting featured advances in pancreatic cancer treatment, focusing on KRAS and vaccines,
Two Years, Two Diagnoses, Two Chemotherapies, and Two Doctors
Jeanne Jeffries struggled with pain, digestive problems, and itchy skin for two years before getting diagnosed with stage IV pancreatic cancer.
An Update on Drugs for KRAS Mutations
Drugs for KRAS are the focus of a number of clinical trials, and Dr. Allyson Ocean comments on the status of this research.
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
Rewinding 2025: A Year in Pancreatic Cancer Research
We take a look back at the research developments in 2025: KRAS, earlier detection and screening, vaccines, and clinical trials.
The Latest Research from the 2025 AACR Special Conference
Highlights from the 2025 AACR Special Conference on pancreatic cancer research include updates on drugs that work on KRAS, AI and early detection, and biomarkers.
“Off-the-Shelf” Vaccine Improves Overall and Average Relapse Survival
Dr. Zev Wainberg provides an update on the effectiveness of a vaccine, with results showing it extends the time to relapse in many patients.
Ready to Fight
Russell Reed lost his father-in-law to pancreatic cancer so he knew how important the right doctor would be for his own treatment.
Treating Cancer By Mutation, Not by Tumor Location
Dr. Conan Kinsey outlines the latest basket trials, which focus on tumor mutation, not the location of the cancer.
RASolute 302 Trial for KRAS and Other RAS Mutations Recruiting at Multiple Sites
Dr. Hani Babiker is optimistic about the new drug to treat patients with KRAS mutations, now in a phase III trial.
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
New Phase III Clinical Trial Actively Recruiting
Dr. Zev Wainberg is enthusiastic about the phase III clinical trial combining a new drug and standard chemo to make immunotherapy more effective.